RX Direct Pharmacy, Inc.; Dismissal of Proceeding, 54070-54072 [E7-18512]
Download as PDF
54070
Federal Register / Vol. 72, No. 183 / Friday, September 21, 2007 / Notices
mstockstill on PROD1PC66 with NOTICES
Drug
Schedule
Cathinone (1235) ..........................
Methcathinone (1237) ..................
N-Ethylamphetamine (1475) ........
Methaqualone (2565) ...................
Gamma-Hydroxybutyric
Acid
(2010).
Lysergic acid diethylamide (7315)
2,5-Dimethoxy-4-(n)propylthiophenethylamine
(7348).
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
3,4,5-Trimethoxyamphetamine
(7390).
4-Bromo-2–5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphyenethylamine
(7392).
4-Methyl-2,5dimethoxyamphetamine (7395).
2,5-Dimethoxyamphetamine
(7396).
2,5-Dimethoxy-4ethylamphetamine (7399).
3,4-Methylenedioxyamphetamine
(7400).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (7405).
4-Methoxyamphetamine (7411) ...
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
Acetyldihydrocodeine (9051) ........
Dihydromorphine (9145) ...............
Heroin (9200) ...............................
Normorphine (9313) .....................
Pholcodine (9314) ........................
Tilidine (9750) ...............................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Phencyclidine (7471) ....................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Benzoylecgonine (9180) ...............
Ethylmorphine (9190) ...................
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Meperidine (9230) ........................
Methadone (9250) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Alfentanil (9737) ...........................
Fentanyl (9801) ............................
Sufentanil (9740) ..........................
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
Dated: September 17, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–18704 Filed 9–20–07; 8:45 am]
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
II
II
II
II
II
II
The company plans to import
analytical reference standards for
distribution to its customers for research
and analytical purposes.
VerDate Aug<31>2005
18:17 Sep 20, 2007
Jkt 211001
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and § 952(a)
and determined that the registration of
Lipomed, Inc. to import the basic
classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated
Lipomed, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and § 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
By Notice dated July 24, 2007 and
published in the Federal Register on
July 30, 2007, (72 FR 41527), Wildlife
Laboratories, 1401 Duff Drive, Suite 400,
Fort Collins, Colorado 80524, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of
Etorphine Hydrochloride (9059), a basic
class of controlled substance listed in
schedule II.
The company plans to import the
listed controlled substance for sale to its
customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Wildlife Laboratories to import the basic
classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated Wildlife
Laboratories to ensure that the
company’s registration is consistent
PO 00000
Frm 00091
Fmt 4703
Sfmt 4703
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: September 17, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–18676 Filed 9–20–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 04–58]
RX Direct Pharmacy, Inc.; Dismissal of
Proceeding
On May 17, 2004, I, the Deputy
Administrator of the Drug Enforcement
Administration, issued an Order to
Show Cause and further ordered the
immediate suspension of DEA
Certificate of Registration, BR8263876,
issued to RX Direct Pharmacy, Inc.
(Respondent) of Deerfield Beach,
Florida. The Order of Immediate
Suspension was based on my
preliminary finding that Respondent,
‘‘through its Internet service[,] has been
responsible for the diversion of large
quantities of controlled substances,’’ Id.
at 9, and that its continued registration
during the pendency of the proceeding,
‘‘would constitute an imminent danger
to the public health and safety because
of the substantial likelihood that [it
would] continue to divert controlled
substances.’’ Id. at 10.
The Show Cause Order proposed the
revocation of Respondent’s registration
as a retail pharmacy and to deny any
pending applications for renewal or
modification of the registration on the
ground that Respondent’s continued
registration would be inconsistent with
the public interest. Show Cause Order at
1 (citing 21 U.S.C. 823(f) & 824(a)). More
specifically, the Show Cause Order
alleged that Respondent’s customers
would access an affiliated Web site, at
which they would complete an on-line
questionnaire and list what drugs they
were seeking. Id. at 5. According to the
Show Cause Order, the questionnaires
were then submitted to ‘‘affiliated
physicians,’’ who would review the
E:\FR\FM\21SEN1.SGM
21SEN1
mstockstill on PROD1PC66 with NOTICES
Federal Register / Vol. 72, No. 183 / Friday, September 21, 2007 / Notices
questionnaires; if the physician
approved the patient’s request, the
prescription was then forwarded to
Respondent to be filled. Id.
The Show Cause Order further alleged
that on four separate occasions between
November 24, 2003, and April 8, 2004,
DEA investigators purchased various
Schedule IV controlled substances
including phentermine, Ambien, and
Meridia, all of which were ordered
through an Internet site and were filled
by Respondent. Id. at 6–8. The Show
Cause Order generally alleged that
prescriptions were based solely on an
Internet questionnaire, that the
investigator never had any contact with
the prescribing physician, and that a
pharmacist never contacted the
investigators to discuss their
prescriptions. See id. Relatedly, the
Show Cause Order also alleged that
between March 22, 2004, and April 13,
2004, Respondent dispensed to a
Pennsylvania resident 600 hydrocodone
tablets, which were prescribed by a
Puerto Rico-based physician. Id. at 8.
On June 11, 2004, Respondent timely
requested a hearing. The matter was
assigned to Administrative Law Judge
(ALJ) Mary Ellen Bittner. At the request
of both parties, various stays were
entered in the matter.
On October 10, 2006, the Government
moved for summary disposition. The
basis of the Government’s motion was
that Respondent’s state pharmacy
license had expired on February 28,
2005, and that Respondent was now
closed. Gov. Mot. For Summary
Judgment at 1. The Government thus
maintained that because Respondent no
longer had authority to handle
controlled substances under Florida
law, it was not entitled to maintain its
DEA registration. Id. at 3. Alternatively,
the Government argued that
Respondent’s DEA registration
automatically terminated when it
closed. Id. at 4 (citing 21 CFR
1301.52(a)).
Respondent opposed the
Government’s motion. Respondent
admitted that its state license had
expired, that it did not renew the
license, and that it had surrendered the
license. Resp. Opp. at 3. Respondent
also ‘‘acknowledge[d] that under
relevant law and precedent, DEA may
not register an applicant to handle
controlled substances if the applicant
lacks authority to handle controlled
substances in the state in which it
practices.’’ Id. Respondent asserted,
however, that this rule should not be
applied to it because of ‘‘the unique
circumstances’’ wherein it ‘‘surrendered
its state pharmacy license after, and
based solely on, DEA’s Order to Show
VerDate Aug<31>2005
18:17 Sep 20, 2007
Jkt 211001
Cause and Immediate Suspension of
[its] DEA registration and where there
has been no opportunity for a
hearing.’’ 1 Id. Respondent further
contended that it ‘‘surrendered its state
license and did not request a hearing
* * * based on the fact that DEA’s
action prevented [it] from operating as
a pharmacy in Florida.’’ 2 Id. at 4.
Respondent thus argued that ‘‘[i]n light
of the peculiar circumstances involved
in this matter, it would be
fundamentally unfair to revoke or
terminate Respondent’s DEA
registration with[out] the opportunity
for an administrative hearing.’’ Id. at 5.
The ALJ did not find Respondent’s
arguments persuasive. Accordingly, as
there were no material facts in dispute,
the ALJ granted the Government’s
motion and forwarded the record to me
for final agency action and
recommended that I revoke
Respondent’s registration. ALJ Dec. at 6.
While reviewing this matter, it was
determined that Respondent’s DEA
registration expired on April 30, 2006,
nearly six months before the
Government moved for summary
disposition. Moreover, Respondent did
not file a renewal application.
Accordingly, I ordered the parties to
brief the issue of whether the case had
become moot or whether there were
collateral consequences that rendered
the case a live controversy. See Ronald
J. Riegel, 63 FR 67132, 67133 (1998) (‘‘If
a registrant has not submitted a timely
renewal application prior to the
expiration date, then the registration
expires and there is nothing to
revoke.’’); see also William R. Lockridge,
71 FR 77791, 77797 (2006) (holding case
not moot because of collateral
consequences). Subsequently, both
parties briefed the issue.
The Government argues that while
there are collateral consequences
pertaining to the forfeiture of controlled
substances that were seized at the time
the immediate suspension was served,
‘‘a section 824(f) asset forfeiture is
1 Respondent further maintained that it was
‘‘financially impossible’’ for it ‘‘to maintain its state
pharmacy license’’ because ‘‘under Florida law,’’ it
was required to keep its prescription department
‘‘ ‘open for a minimum of forty (40) hours per week
and a minimum of five (5) days per week.’ ’’ Id. at
4–5 (quoting Fla. Adm. Code 64B16–28.1018).
According to Respondent, it would have
maintained its state license ‘‘but for this practical
impossibility.’’ Id. at 5. Respondent also contended
that because the Government seized all of its
records and equipment, it ‘‘made it difficult, if not
impossible, for Respondent to conduct its pharmacy
business.’’ Id. at 2.
2 In support of its position, Respondent cited my
Order in Oakland Medical Pharmacy, 71 FR 50,100
(2006). Specifically, Respondent relied on the ALJ’s
reasoning in that case which I expressly declined
to follow.
PO 00000
Frm 00092
Fmt 4703
Sfmt 4703
54071
predicated ‘[u]pon a revocation order
becoming final.’ ’’ Gov. Resp. to Briefing
Order at 3 (quoting 21 U.S.C. 824(f)).
The Government notes that this leads to
‘‘disparate dispositions’’ because the
controlled substances of an entity whose
registration does not expire before the
issuance of a final order are subject to
forfeiture while a registrant can prevent
the Government from obtaining
forfeiture under section 824(f) by
allowing its registration to expire. Id.
The Government nonetheless argues
that ‘‘affirming an immediate
suspension will not trigger the section
824(f) asset forfeiture,’’ and that ‘‘[i]f the
registrant’s registration expires while
OTSC proceedings are in progress and
the registrant does not submit a renewal
application, such a registrant can avoid
the consequences of section 824(f).’’ Id.
at 3–4.
Notably, the Government does not
argue that the statute is silent on the
question of whether forfeiture is
triggered when a registrant requests a
hearing and then allows its registration
to expire before the final order is issued.
Cf. Chevron U.S.A., Inc., v. NRDC, 467
U.S. 837, 843 (1984) (‘‘[I]f the statute is
silent or ambiguous with respect to the
specific issue, the question for the court
is whether the agency’s answer is based
on a permissible construction of the
statute.’’). Instead, the Government
argues that ‘‘these disparate results can
be obviated through other asset
forfeiture proceedings or through
settlements in related civil or criminal
proceedings.’’ Gov. Resp. at 4. The
Government thus concedes that this
case is now moot.
Agreeing with the Government’s
reasoning, Respondent argues that
‘‘§ 824(f) forfeiture proceedings do not
apply in a situation where the
Respondent’s registration expires while
the OTSC proceedings are in progress
and the registrant does not submit a
renewal application.’’ Respondent Resp.
at 5. According to Respondent,
‘‘[w]ithout a final order by DEA to
‘revoke or suspend’ the registration,
DEA may not use § 824(f) to place such
drugs under ‘seal’ and require the
registrant to forfeit the drugs.’’ Id.
Respondent further contends that to
‘‘allow[] the government to permanently
forfeit Respondent’s property without
an opportunity for a full hearing on the
merits is unreasonable and contrary to
law.’’ Id. Respondent thus requests that
I hold that the matter is moot.
Having considered the record and the
parties’ positions, I conclude that this
case is now moot. Respondent allowed
its registration to expire and has not
filed a renewal application. Indeed,
Respondent has surrendered its state
E:\FR\FM\21SEN1.SGM
21SEN1
54072
Federal Register / Vol. 72, No. 183 / Friday, September 21, 2007 / Notices
pharmacy license and closed its
business. Moreover, Respondent has not
asserted that it plans to re-enter the
business of pharmacy at some future
date. See CRJ Pharmacy, Inc., and YPM
Total Care Pharmacy, Inc., 72 FR 30846
(2007).
Finally, as the Government points out,
the United States Attorney has sought
forfeiture of ‘‘any property which the
defendant used or intended to be used
in any manner * * * to commit’’ the
offenses charged in the indictment
which includes the controlled
substances previously seized. See
Indictment, United States of America v.
Frank Hernandez, et al., at 11 (Case #
07–60027–CR, S.D. Fla.). Because title to
the controlled substances will be
determined in the pending criminal
proceeding, this case does not present
any collateral consequence that the
issuance of a final order would resolve.3
Accordingly, this case is now moot.4
Order
Pursuant to the authority vested in me
by 21 U.S.C. 823(f) and 824(a), as well
as 28 CFR 0.100(b) and 0.104, I hereby
order that the Order to Show Cause be,
and it hereby is, dismissed.
Dated: September 13, 2007.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. E7–18512 Filed 9–20–07; 8:45 am]
mstockstill on PROD1PC66 with NOTICES
BILLING CODE 4410–09–P
3 Respondent also requests that ‘‘DEA authorize
[it] to determine whether the controlled substances
still in the government’s possession may be
distributed to an authorized registrant for credit.’’
Respondent’s Resp. at 5. Respondent’s request
should be directed to the Federal District Court. See
21 U.S.C. 824(f).
4 In holding this matter moot, I rely solely on the
factual circumstances and do not adopt the parties’
construction of the statute. Indeed, under that
interpretation, even where a hearing has been held
on the allegations that supported the immediate
suspension order and the seizure of controlled
substances, a respondent could see how it had fared
in the proceeding and if it determined that it was
not likely to prevail, it could then defeat the effect
of the proceeding simply by failing to submit a
renewal application and allowing its registration to
expire. Under the parties’ construction, the hearing
would have been for naught and the Government
would likely be required to relitigate the issues in
another proceeding. It is implausible that Congress
intended such a result.
VerDate Aug<31>2005
18:17 Sep 20, 2007
Jkt 211001
I. Background
DEPARTMENT OF LABOR
Employee Benefits Security
Administration
Proposed Extension of Information
Collection Request Submitted for
Public Comment and
Recommendations; Mental Health
Parity
Employee Benefits Security
Administration, Department of Labor.
AGENCY:
ACTION:
Notice.
SUMMARY: The Department of Labor, as
part of its continuing effort to reduce
paperwork and respondent burden,
conducts a preclearance consultation
program to provide the general public
and other federal agencies with an
opportunity to comment on proposed
and continuing collections of
information in accordance with the
Paperwork Reduction Act of 1995 (PRA
95) (44 U.S.C. 3506(c)(2)(A)). This
program helps to ensure that requested
data is provided in the desired format,
reporting burden (time and financial
resources) is minimized, collection
instruments are clearly understood, and
the impact of collection requirements on
respondents can be properly assessed.
By this notice, the Department of
Labor’s Employee Benefits Security
Administration (EBSA) is soliciting
comments on the extension of the
information collection requests (ICRs)
included in the Interim Rules for Mental
Health Parity as published in the
Federal Register on December 22, 1997
(62 FR 66931) (Interim Rules). OMB
approved the two separate ICRs under
OMB control numbers 1210–0105 and
1210–0106, which expire on January 31,
2008, and October 31, 2008,
respectively. Copies of the ICRs may be
obtained by contacting the office shown
below in the ADDRESSES section of this
notice.
Written comments must be
submitted to the office listed in the
ADDRESSES section on or before
November 20, 2007.
DATES:
Interested parties are
invited to submit written comments
regarding the ICRs to Mr. Joseph S.
Piacentini, Office of Policy and
Research, U.S. Department of Labor,
Employee Benefits Security
Administration, 200 Constitution
Avenue, NW., Room N–5647,
Washington, DC 20210. Telephone:
(202) 219–8410. Fax: (202) 219–4745
(these are not toll-free numbers).
ADDRESSES:
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00093
Fmt 4703
Sfmt 4703
The purpose of this notice is to seek
comments from the public prior to
submission to OMB for continued
approval of two information collection
requests included in the Interim Final
Rules. The Mental Health Parity Act of
1996 (MHPA) (Pub. L. 104–204)
generally requires that group health
plans provide parity in the application
of dollar limits between mental health
and medical/surgical benefits. The
statute exempts plans from this
requirement if its application results in
an increase in the cost under the plan
or coverage by at least one percent. The
Interim Final Rules under 29 CFR
2590.712(f)(3)(i) and (ii) require a group
health plan electing to take advantage of
this exemption to provide a written
notice to participants and beneficiaries
and to the federal government of the
plan’s election. This notice requirement
is approved under OMB control number
1210–0105. To satisfy the requirement
to notify the federal government, a
group health plan may either send the
Department a copy of the summary of
material reductions in covered services
or benefits sent to participants and
beneficiaries, or the plan may use the
Department’s model notice published in
the Interim Final Rule which was
developed for this purpose.
The second ICR, approved under
OMB control number 1210–0106, is a
summary of the information used to
calculate the plan’s increased costs
under the MHPA for purposes of
electing the one percent increased cost
exemption. The plan is required to make
a copy of the summary available to
participants and beneficiaries, on
request at no charge. Under 29 CFR
2590.712(f)(2), a group health plan
wishing to elect the one percent
exemption must calculate their
increased costs according to certain
rules.
II. Desired Focus of Comments
The Department of Labor is
particularly interested in comments
that:
• Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
• Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
• Enhance the quality, utility, and
clarity of the information to be
collected; and
E:\FR\FM\21SEN1.SGM
21SEN1
Agencies
[Federal Register Volume 72, Number 183 (Friday, September 21, 2007)]
[Notices]
[Pages 54070-54072]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-18512]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 04-58]
RX Direct Pharmacy, Inc.; Dismissal of Proceeding
On May 17, 2004, I, the Deputy Administrator of the Drug
Enforcement Administration, issued an Order to Show Cause and further
ordered the immediate suspension of DEA Certificate of Registration,
BR8263876, issued to RX Direct Pharmacy, Inc. (Respondent) of Deerfield
Beach, Florida. The Order of Immediate Suspension was based on my
preliminary finding that Respondent, ``through its Internet service[,]
has been responsible for the diversion of large quantities of
controlled substances,'' Id. at 9, and that its continued registration
during the pendency of the proceeding, ``would constitute an imminent
danger to the public health and safety because of the substantial
likelihood that [it would] continue to divert controlled substances.''
Id. at 10.
The Show Cause Order proposed the revocation of Respondent's
registration as a retail pharmacy and to deny any pending applications
for renewal or modification of the registration on the ground that
Respondent's continued registration would be inconsistent with the
public interest. Show Cause Order at 1 (citing 21 U.S.C. 823(f) &
824(a)). More specifically, the Show Cause Order alleged that
Respondent's customers would access an affiliated Web site, at which
they would complete an on-line questionnaire and list what drugs they
were seeking. Id. at 5. According to the Show Cause Order, the
questionnaires were then submitted to ``affiliated physicians,'' who
would review the
[[Page 54071]]
questionnaires; if the physician approved the patient's request, the
prescription was then forwarded to Respondent to be filled. Id.
The Show Cause Order further alleged that on four separate
occasions between November 24, 2003, and April 8, 2004, DEA
investigators purchased various Schedule IV controlled substances
including phentermine, Ambien, and Meridia, all of which were ordered
through an Internet site and were filled by Respondent. Id. at 6-8. The
Show Cause Order generally alleged that prescriptions were based solely
on an Internet questionnaire, that the investigator never had any
contact with the prescribing physician, and that a pharmacist never
contacted the investigators to discuss their prescriptions. See id.
Relatedly, the Show Cause Order also alleged that between March 22,
2004, and April 13, 2004, Respondent dispensed to a Pennsylvania
resident 600 hydrocodone tablets, which were prescribed by a Puerto
Rico-based physician. Id. at 8.
On June 11, 2004, Respondent timely requested a hearing. The matter
was assigned to Administrative Law Judge (ALJ) Mary Ellen Bittner. At
the request of both parties, various stays were entered in the matter.
On October 10, 2006, the Government moved for summary disposition.
The basis of the Government's motion was that Respondent's state
pharmacy license had expired on February 28, 2005, and that Respondent
was now closed. Gov. Mot. For Summary Judgment at 1. The Government
thus maintained that because Respondent no longer had authority to
handle controlled substances under Florida law, it was not entitled to
maintain its DEA registration. Id. at 3. Alternatively, the Government
argued that Respondent's DEA registration automatically terminated when
it closed. Id. at 4 (citing 21 CFR 1301.52(a)).
Respondent opposed the Government's motion. Respondent admitted
that its state license had expired, that it did not renew the license,
and that it had surrendered the license. Resp. Opp. at 3. Respondent
also ``acknowledge[d] that under relevant law and precedent, DEA may
not register an applicant to handle controlled substances if the
applicant lacks authority to handle controlled substances in the state
in which it practices.'' Id. Respondent asserted, however, that this
rule should not be applied to it because of ``the unique
circumstances'' wherein it ``surrendered its state pharmacy license
after, and based solely on, DEA's Order to Show Cause and Immediate
Suspension of [its] DEA registration and where there has been no
opportunity for a hearing.'' \1\ Id. Respondent further contended that
it ``surrendered its state license and did not request a hearing * * *
based on the fact that DEA's action prevented [it] from operating as a
pharmacy in Florida.'' \2\ Id. at 4. Respondent thus argued that ``[i]n
light of the peculiar circumstances involved in this matter, it would
be fundamentally unfair to revoke or terminate Respondent's DEA
registration with[out] the opportunity for an administrative hearing.''
Id. at 5.
---------------------------------------------------------------------------
\1\ Respondent further maintained that it was ``financially
impossible'' for it ``to maintain its state pharmacy license''
because ``under Florida law,'' it was required to keep its
prescription department `` `open for a minimum of forty (40) hours
per week and a minimum of five (5) days per week.' '' Id. at 4-5
(quoting Fla. Adm. Code 64B16-28.1018). According to Respondent, it
would have maintained its state license ``but for this practical
impossibility.'' Id. at 5. Respondent also contended that because
the Government seized all of its records and equipment, it ``made it
difficult, if not impossible, for Respondent to conduct its pharmacy
business.'' Id. at 2.
\2\ In support of its position, Respondent cited my Order in
Oakland Medical Pharmacy, 71 FR 50,100 (2006). Specifically,
Respondent relied on the ALJ's reasoning in that case which I
expressly declined to follow.
---------------------------------------------------------------------------
The ALJ did not find Respondent's arguments persuasive.
Accordingly, as there were no material facts in dispute, the ALJ
granted the Government's motion and forwarded the record to me for
final agency action and recommended that I revoke Respondent's
registration. ALJ Dec. at 6.
While reviewing this matter, it was determined that Respondent's
DEA registration expired on April 30, 2006, nearly six months before
the Government moved for summary disposition. Moreover, Respondent did
not file a renewal application. Accordingly, I ordered the parties to
brief the issue of whether the case had become moot or whether there
were collateral consequences that rendered the case a live controversy.
See Ronald J. Riegel, 63 FR 67132, 67133 (1998) (``If a registrant has
not submitted a timely renewal application prior to the expiration
date, then the registration expires and there is nothing to revoke.'');
see also William R. Lockridge, 71 FR 77791, 77797 (2006) (holding case
not moot because of collateral consequences). Subsequently, both
parties briefed the issue.
The Government argues that while there are collateral consequences
pertaining to the forfeiture of controlled substances that were seized
at the time the immediate suspension was served, ``a section 824(f)
asset forfeiture is predicated `[u]pon a revocation order becoming
final.' '' Gov. Resp. to Briefing Order at 3 (quoting 21 U.S.C.
824(f)). The Government notes that this leads to ``disparate
dispositions'' because the controlled substances of an entity whose
registration does not expire before the issuance of a final order are
subject to forfeiture while a registrant can prevent the Government
from obtaining forfeiture under section 824(f) by allowing its
registration to expire. Id. The Government nonetheless argues that
``affirming an immediate suspension will not trigger the section 824(f)
asset forfeiture,'' and that ``[i]f the registrant's registration
expires while OTSC proceedings are in progress and the registrant does
not submit a renewal application, such a registrant can avoid the
consequences of section 824(f).'' Id. at 3-4.
Notably, the Government does not argue that the statute is silent
on the question of whether forfeiture is triggered when a registrant
requests a hearing and then allows its registration to expire before
the final order is issued. Cf. Chevron U.S.A., Inc., v. NRDC, 467 U.S.
837, 843 (1984) (``[I]f the statute is silent or ambiguous with respect
to the specific issue, the question for the court is whether the
agency's answer is based on a permissible construction of the
statute.''). Instead, the Government argues that ``these disparate
results can be obviated through other asset forfeiture proceedings or
through settlements in related civil or criminal proceedings.'' Gov.
Resp. at 4. The Government thus concedes that this case is now moot.
Agreeing with the Government's reasoning, Respondent argues that
``Sec. 824(f) forfeiture proceedings do not apply in a situation where
the Respondent's registration expires while the OTSC proceedings are in
progress and the registrant does not submit a renewal application.''
Respondent Resp. at 5. According to Respondent, ``[w]ithout a final
order by DEA to `revoke or suspend' the registration, DEA may not use
Sec. 824(f) to place such drugs under `seal' and require the
registrant to forfeit the drugs.'' Id. Respondent further contends that
to ``allow[] the government to permanently forfeit Respondent's
property without an opportunity for a full hearing on the merits is
unreasonable and contrary to law.'' Id. Respondent thus requests that I
hold that the matter is moot.
Having considered the record and the parties' positions, I conclude
that this case is now moot. Respondent allowed its registration to
expire and has not filed a renewal application. Indeed, Respondent has
surrendered its state
[[Page 54072]]
pharmacy license and closed its business. Moreover, Respondent has not
asserted that it plans to re-enter the business of pharmacy at some
future date. See CRJ Pharmacy, Inc., and YPM Total Care Pharmacy, Inc.,
72 FR 30846 (2007).
Finally, as the Government points out, the United States Attorney
has sought forfeiture of ``any property which the defendant used or
intended to be used in any manner * * * to commit'' the offenses
charged in the indictment which includes the controlled substances
previously seized. See Indictment, United States of America v. Frank
Hernandez, et al., at 11 (Case 07-60027-CR, S.D. Fla.).
Because title to the controlled substances will be determined in the
pending criminal proceeding, this case does not present any collateral
consequence that the issuance of a final order would resolve.\3\
Accordingly, this case is now moot.\4\
---------------------------------------------------------------------------
\3\ Respondent also requests that ``DEA authorize [it] to
determine whether the controlled substances still in the
government's possession may be distributed to an authorized
registrant for credit.'' Respondent's Resp. at 5. Respondent's
request should be directed to the Federal District Court. See 21
U.S.C. 824(f).
\4\ In holding this matter moot, I rely solely on the factual
circumstances and do not adopt the parties' construction of the
statute. Indeed, under that interpretation, even where a hearing has
been held on the allegations that supported the immediate suspension
order and the seizure of controlled substances, a respondent could
see how it had fared in the proceeding and if it determined that it
was not likely to prevail, it could then defeat the effect of the
proceeding simply by failing to submit a renewal application and
allowing its registration to expire. Under the parties'
construction, the hearing would have been for naught and the
Government would likely be required to relitigate the issues in
another proceeding. It is implausible that Congress intended such a
result.
---------------------------------------------------------------------------
Order
Pursuant to the authority vested in me by 21 U.S.C. 823(f) and
824(a), as well as 28 CFR 0.100(b) and 0.104, I hereby order that the
Order to Show Cause be, and it hereby is, dismissed.
Dated: September 13, 2007.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. E7-18512 Filed 9-20-07; 8:45 am]
BILLING CODE 4410-09-P